Date: 2016-10-18
Type of information: Nomination
Compound:
Company: Polyphor (Switzerland)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 18, 2016, Polyphor has announced the appointment of Giacomo Di Nepi as the new CEO. He will assume responsibilities on November 1st, 2016. Michael Altorfer will support Giacomo over the coming months to facilitate the transition and then leave the company to pursue other opportunities. Giacomo Di Nepi has been advising the Board of Directors of Polyphor on strategy and organization since last May. He has a long and successful career in the Pharma/Biotech industry where he launched several products at country, regional and global level and developed broad leadership skills across a variety of general management positions. Giacomo brings over 30 years’ experience in the industry, most recently as EVP and General Manager, Europe for InterMune, where he launched Esbriet, drug, and built from scratch a $ 140 million and 200 people business – until the acquisition of InterMune by Roche for USD 8.3bn. Prior, he was in senior leadership responsibilities with Takeda and Novartis, where he was also member of the Pharma Executive Committee, and was a Partner with McKinsey&Co. He currently serves on the boards of Geneuro and NTC, a privately held company.
Financial terms:
Latest news:
